Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Ascendis Pharma A/S    ASND

ASCENDIS PHARMA A/S (ASND)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
OFFRE
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/17/2018 09/18/2018 09/19/2018 09/20/2018 09/21/2018 Date
68.18(c) 67.83(c) 67.5(c) 67.5(c) 66.5(c) Last
72 894 78 219 78 190 111 746 212 446 Volume
-0.23% -0.51% -0.49% 0.00% -1.48% Change
More quotes
Financials (EUR)
Sales 2018 1,20 M
EBIT 2018 -176 M
Net income 2018 -166 M
Finance 2018 251 M
Yield 2018 -
Sales 2019 1,78 M
EBIT 2019 -188 M
Net income 2019 -205 M
Finance 2019 122 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 1 784x
EV / Sales2019 1 280x
Capitalization 2 399 M
More Financials
Company
Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates.Through its TransCon technology, it develops a pipeline of sustained release prodrug therapies including endocrinology product candidates to support the market.The company was founded by Jan... 
Sector
Biotechnology & Medical Research
Calendar
09/26 | 05:00pmPresentation
More about the company
Surperformance© ratings of Ascendis Pharma A/S
Trading Rating : Investor Rating :
More Ratings
Latest news on ASCENDIS PHARMA A/S
09/19ASCENDIS PHARMA A/S : Announces Support for Children's Growth Awareness Week and..
AQ
09/18ASCENDIS PHARMA A/S : Announces Support for Childrens Growth Awareness Week and ..
AQ
09/17Ascendis Pharma A/S Announces Support for Children’s Growth Awareness W..
GL
09/11ASCENDIS PHARMA A/S : Announces Presentations on Technology and Rare Disease End..
AQ
09/06Ascendis Pharma A/S Announces Presentations on Technology and Rare Disease En..
GL
09/03ASCENDIS PHARMA A/S : Announces Upcoming Investor Presentations
AQ
08/31Ascendis Pharma A/S Announces Upcoming Investor Presentations
GL
08/31ASCENDIS PHARMA A/S : Reports Second Quarter 2018 Financial Results
AQ
08/29Ascendis Pharma A/S Reports Second Quarter 2018 Financial Results
GL
08/29ASCENDIS PHARMA A/S : Sponsored ADR to Host Earnings Call
AC
More news
Sector news : Bio Therapeutic Drugs
09/19NOVARTIS : U.K. Pulls Brakes on Novartis' CAR-T Drug in First European Setback -..
DJ
09/19NOVARTIS : U.K. Pulls Brakes on Novartis' CAR-T Drug for Some Patients Despite D..
DJ
09/19GILEAD SCIENCES : UK rejects adult Novartis CAR-T therapy, after 'yes' in kids
RE
09/18REGENERON PHARMACEUTICALS : Sanofi pledges to keep up its restructuring efforts
RE
09/14Allogene, Which Announced Pfizer Agreement in April, Discloses IPO Plans
DJ
More sector news : Bio Therapeutic Drugs
Latest Tweets
09/18Ascendis Pharma A/S Announces Support for Children’s Growth Awareness Week an.. 
09/14Don't miss this week's Peer Review from -- Top scientist Thor Voigt vaults t..
3
09/12Comparing Ascendis Pharma A/S $ASND and Ultragenyx Pharmaceutical $RARE  
09/09Analysts Expect Ascendis Pharma A/S $ASND Will Post Earnings of -$1.19 Per Sh.. 
09/08Ascendis Pharma A/S $ASND Stock Rating Lowered by BidaskClub  
More tweets
Qtime:104
News from SeekingAlpha
08/29Ascendis Pharma (ASND) CEO Jan Mikkelsen on Q2 2018 Results - Earnings Call T.. 
08/29Ascendis Pharma  reports Q2 results 
08/07Premarket analyst action - healthcare 
06/28Entera Bio Aims Lower For Improved IPO Terms 
06/16INSTITUTIONAL TOP IDEAS : Cormorant Asset Management 
Chart ASCENDIS PHARMA A/S
Duration : Period :
Ascendis Pharma A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASCENDIS PHARMA A/S
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Average target price 67,6 €
Spread / Average Target 18%
EPS Revisions
Managers
NameTitle
Jan Møller Mikkelsen President, Chief Executive Officer & Director
Michael Wolff Jensen Chairman, SVP & General Counsel
Neil T. Ringdahl Chief Operating Officer
Scott T. Smith Chief Financial Officer & Senior Vice President
Harald Rau Chief Scientific Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ASCENDIS PHARMA A/S66.00%2 826
GILEAD SCIENCES5.40%97 005
VERTEX PHARMACEUTICALS20.17%46 134
REGENERON PHARMACEUTICALS3.81%41 105
NEUROCRINE BIOSCIENCES, INC.54.17%10 877
GENMAB1.90%10 184